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ABSTRACT 
Ursolic acid (UA) is a pentacyclic triterpenoid carboxylic acid that is found in plants and 
herbal products. It is one of the chemopreventive agents, which can suppress cancer cell pro-
liferation and induce apoptosis. UA possesses various biological activities including anti-
cancer, anti-inflammatory, anti-oxidative and hepatoprotective activity. We investigated the 
effect of UA on cytokine production via the MAPK pathways in Jurkat leukemic T-cells, 
showing that UA inhibited cell growth and proliferation of Jurkat cells, as well as suppressing 
PMA/PHA induced IL-2 and TNF-α production in a concentration and time dependent man-
ner. The inhibition of IL-2 and TNF-α production by UA involved the c-Jun N-terminal ki-
nase (JNK) pathway, but not the extracellular-signal regulated protein kinase (ERK) pathway. 
Future utilization of UA as a chemopreventive or therapeutic agent may provide an alternative 
option for leukemia treatments.  
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INTRODUCTION 
Leukemia is a malignancy of the blood 
resulting in an increase of immature white 
blood cells with abnormal functions. The 
conventional treatment for patients suffer-
ing from leukemia is chemotherapy, in 
which patients encounter many adverse side 
effects. To reduce these side effects, alter-
native medicines in combination with con-
ventional treatments could provide other 
options for treatment of leukemia. Ursolic 
acid, a pentacyclic triterpenoid carboxylic 
acid found in plants, has various biological 
properties, including anti-inflammatory, 
anticancer, anti-angiogenic, and anti-
oxidative activities (Cardenas et al., 2004; 
Ikeda et al., 2008; Manu and Kuttan, 2008; 
Tang et al., 2009; Zhang et al., 2009; Wu et 
al., 2010; Limami et al., 2011; Zheng et al., 
2012). Apoptosis induced by UA occurs 
through multiple pathways, such as the in-
hibition of DNA replication, down-
regulation of anti-apoptotic proteins, sup-
pression of nuclear factor (NF)-B activa-
tion, as well as other pathways (Cardenas et 
al., 2004; Ikeda et al., 2008; Manu and 
Kuttan, 2008; Tang et al., 2009; Zhang et 
al., 2009; Yadav et al., 2010). UA can in-
hibit gene expression of pro-inflammatory 
cytokines and suppress transcription factors 
leading to apoptosis in B16F-10 melanoma 
cells (Manu and Kuttan, 2008). Cytokines 
are involved in signal transduction resulting 
in the activation of genes for growth and 
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differentiation, and various other cellular 
activates. Pro-inflammatory cytokines such 
as interleukin-2 (IL-2) and tumor necrosis 
factor alpha (TNF-) have both; im-
munostimulatory and immunosuppressive 
functions (O'Shea et al., 2002; Bachmann 
and Oxenius, 2007). Maximal IL-2 produc-
tion in Jurkat cells can be stimulated via 
two signaling pathways; the first can be ini-
tiated using the ligand for the T-cell recep-
tor (TCR) along with a CD3 specific anti-
body, and the second by phorbol esters 
(TPA) and calcium ionophore or co-
stimulation (Abraham and Weiss, 2004). T-
cell stimulation through protein kinase C 
(PKC) activates multiple pathways result-
ing in the production of many transcription 
factors and cytokines including IL-2 
(Altman et al., 2000). A previous study has 
shown that UA regulation of inflammatory 
cytokines in T- and B-lymphocytes, in-
volves transcription factors such as NF-B, 
nuclear factor of activated T cells (NF-AT) 
and AP-1 along with the mitogen-activated 
protein kinase (MAPK) pathways (Checker 
et al., 2012). 
The MAPK signaling pathways, includ-
ing the signaling proteins, extracellular-
signal regulated protein (ERK), c-Jun N-
terminal kinase (JNK) and p38 MAPK are 
involved in the activation of T-cells in the 
immune response, regulation of gene ex-
pression, cell proliferation and programmed 
cell death in mammalian cells (Chang and 
Karin, 2001; Dong et al., 2002; Platanias, 
2003). The ERK pathway can mediate cell 
proliferation and apoptosis depending on 
the stimuli and cell type (Mebratu and 
Tesfaigzi, 2009), whereas activation of JNK 
regulates T-cell differentiation in the im-
mune system through TCR and the co-
stimulation molecule CD28, resulting in the 
expression of IL-2 (Karin and Gallagher, 
2005). Other studies show that fibroblasts, 
which lack expression of all isoforms of 
JNK (JNK-null), also show severe defects 
in c-Jun expression, TNF-stimulated AP-1 
expression and AP-1 DNA-binding activity, 
which are essential for cytokine production 
(Cloutier et al., 2003; Kennedy and Davis, 
2003; Ventura et al., 2003). JNK is also in-
volved in both the extrinsic and intrinsic 
apoptotic pathways (Dhanasekaran and 
Reddy, 2008). Furthermore, UA induced 
apoptosis in DU145 prostate cancer cells 
and human leukemia K562 cells, which oc-
curs through the activation of the JNK 
pathway (Liu and Jiang, 2007; Zhang et al., 
2009). However, the mechanism by which 
UA effects cytokine production in leukemia 
T-cells has not been fully identified. In the 
present study we investigated the effects of 
UA on IL-2 and TNF- production via the 
MAPK pathways in human leukemic Jurkat 
T-cells. 
 
MATERIALS AND METHODS 
Cell culture 
Jurkat leukemic T-cell lines were cul-
tured in RPMI-1640 (Hyclone, USA) sup-
plemented with 10 % heat-inactivated fetal 
bovine serum (FBS). The cells were main-
tained in logarithmic growth at 37 C in a 
humidified atmosphere containing a mix-
ture of air and 5 % CO2. Ursolic acid (UA: 
3-hydroxy-12-urs-12-en-28-oic acid) 
(Sigma Aldrich, Switzerland) was dissolved 
in DMSO at 25 mM and stored at 4 C. 
 
Cell viability assay 
Cell viability was determined using the 
XTT assay kit (Sigma Aldrich, USA). 
Jurkat cells (1x106 cells ml-1) were seeded 
in 96-well plates, treated with UA and 
maintained in normal culture conditions for 
12 hours. As a control, DMSO was added 
to the culture at < 0.1 %. XTT working so-
lution (20 µl) was then added into each well 
and incubated for 4 hours before the ab-
sorbance was read at a wavelength of 
450 nm with a reference 690 nm using a 
microtiter plate reader (BioTek, USA). 
Three independent XTT experiments were 
performed and the final percent cell viabil-
ity was calculated. 
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Enzyme-linked immunosorbent assay 
(ELISA) of IL-2 and TNF-α 
Jurkat cells (1x106 cells ml-1) were 
treated with 20 M UA or, as a positive 
control, 12.5 ng ml-1 Phorbol 12-Myristate 
13-Acetate (PMA) plus 0.25 µg ml-1 Lectin 
from Phaseolus vulgaris/Leucoagglutinin 
(PHA-L) (Sigma Aldrich, USA), and incu-
bated for 1 to 24 hours. Cells were also 
treated with < 0.1 % DMSO as a vehicle 
control. To test cytokine inhibition, cells 
were treated with UA, 20 µM ERK inhibi-
tor (PD98059) or 20 µM JNK inhibitor 
(SP600125) (Sigma Aldrich, USA) for be-
tween 0 and 12 hours prior to the addition 
of PMA/PHA. The cells were then incubat-
ed a further 12 hours before the culture me-
dia was collected and stored at -70 C such 
that the IL-2 and TNF-α levels could be de-
termined using the ELISA kit (R&D Sys-
tems, USA) at a later date. The absorbance 
was read at wavelength of 450 nm with a 
reference 540 nm using a microtiter plate 
reader (Perkin Elmer, Finland). Cytokine 
level was normalized to the total protein 
concentration of the viable cell pellets using 
the Bradford method with Bio-Rad protein 
assay reagent (Bio-Rad, CA). ELISA data 
were determined from three independent 
experiments. 
 
Western blot analysis 
Jurkat cells (1x106 cells ml-1) were 
treated with 20 µM UA or PMA/PHA (pos-
itive control) for between 1 and 24 hours or 
cells were treated with 20 µM UA for be-
tween 0 and 12 hours prior to the addition 
of PMA/PHA for a further 12 hours. The 
cells were then washed with ice-cold phos-
phate-buffered-saline (PBS, pH 7.4) and 
centrifuged at 1,500 rpm for 5 minutes 
three times. Whole cell lysate was prepared 
using lysis buffer containing 25 mM Tris-
phosphate (pH 7.8) 2 mM DTT, 2mM 1,2-
diaminocyclohexane-N,N,N’,N’-tetraacetic 
acid, 10 % glycerol, 1 % Triton® X-100 and 
protease inhibitor cocktail (Sigma Aldrich, 
USA). A total of 5 µg protein extract was 
separated by electrophoresis on a 10 % 
SDS-Polyacrylamide gel and transferred 
onto a Polyvinylidene difluoride (PVDF) 
membrane (Millipore, USA). Membranes 
were blocked with 5 % non-fat milk in 
0.1 % Tween-20 in TBS buffer for 1 hour at 
room temperature. The membranes were 
then incubated with primary antibody 
against p-ERK1/2, ERK1/2, SAPK/JNK, or 
β-actin with a dilution factor of 1:4000 or 
against p-SAPK/JNK with a dilution factor 
of 1:1000, (Cell signaling, USA) at 4 C 
overnight. Membranes were then washed 
with 0.1 % Tween-20 in TBS buffer three 
times and then incubated with horseradish 
peroxidase (HRP) conjugated secondary 
antibodies (1:4000, Cell signaling, USA) 
for 45 minutes. Membranes were again 
washed three times and protein expression 
was detected with enhanced chemilumines-
cence (ECL) western blotting substrate 
(Pierce, USA) and to Hyperfilm-ECL (GE 
healthcare, UK). The intensity of the im-
munoreactive bands from Western blot im-
ages was analyzed using NIH Image J com-
puter software. Western blot analyses were 
performed from three independent experi-
ments. 
 
Statistical analysis 
Statistical analysis of data was per-
formed using one-way analysis of variance 
(ANOVA). Data are expressed as mean 
values  SEM. Values of P < 0.05 are con-
sidered statistically significant. 
 
RESULTS 
Inhibition of leukemic T-cell proliferation 
by ursolic acid  
In this study, we examined whether UA 
inhibited the growth of Jurkat cells in a 
concentration dependent manner. Cells 
were treated with UA (5 to 100 µM) or 
DMSO for 12 hours as described above and 
cell viability was determined using the XTT 
assay. The results show that UA at 30 µM 
and above significantly inhibits cell growth 
(Figure 1), giving an IC50 value of approx-
imately 32.5 µM.  
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Figure 1: Inhibition of leukemic T-cell growth by 
ursolic acid. Jurkat cells were treated with UA 
(5 to 100 M) or DMSO for 12 hours. Cell viabil-
ity was determined using the XTT assay. Re-
sults are expressed as mean  SEM from three 
independent experiments. Statistical analysis 
was carried out with one-way ANOVA followed 
by Tukey’s multiple comparison test compared 
with DMSO (** P < 0.01, *** P < 0.001).  
 
 
Effect of ursolic acid on IL-2 and TNF-α 
production 
We investigated the effect of UA on cy-
tokine production in Jurkat cells, starting 
with either UA or DMSO alone using ELI-
SA, which resulted in no significant effect 
on IL-2 and TNF-α production (data not 
shown). We then treated cells with 
PMA/PHA (12.5 ng ml-1 / 0.25 µg ml-1) to 
observe the time and level of cytokine se-
cretion. The results show that PMA/PHA 
stimulates IL-2 and TNF-α production sig-
nificantly in a time dependent manner com-
pared with control (DMSO) (Figure 2). IL-2 
and TNF-α secretion were significantly in-
creased at 12 hours and 3 hours respecti-
vely. 
 
 
Figure 2: Effect of PMA/PHA on IL-2 and TNF-
 production in Jurkat cells. Cells were treated 
with PMA/PHA (12.5 ng ml-1 / 0.25 µg ml-1) for 1 
to 24 hours. IL-2 and TNF- released to the 
media were determined using ELISA. Results 
are expressed as mean  SEM from three in-
dependent experiments. Statistical analysis was 
carried out with one-way ANOVA followed by 
Tukey’s multiple comparison test compared 
with DMSO control (** P < 0.01, *** P < 0.001). 
 
 
Effect of ursolic acid on inhibition of 
PMA/PHA-induced IL-2 and TNF-α 
 production 
Since UA failed to induce cytokine pro-
duction in Jurkat cells, we therefore inves-
tigated whether UA was able to inhibit 
PMA/PHA-induced IL-2 and TNF-α pro-
duction. The cells were pretreated with var-
ious concentrations of UA, below the IC50 
(32.5 µM), and at various time points prior 
to the addition of PMA/PHA. Using ELISA 
we found that, UA significantly decreased 
the cytokine production compared with that 
of PMA/PHA alone. Furthermore, we found 
that UA inhibits the PMA/PHA stimulated 
production of IL-2 and TNF-α in a time and 
dose dependent manner (Figure 3a, b). Re-
ports have previously shown that MAPK 
pathways are involved in cytokine produc-
tion (Dong et al., 2002; Platanias, 2003), 
therefore in order to investigate whether 
MAPK inhibitors are sufficient to inhibit 
the production of IL-2 and TNF-α, we 
measured the level of IL-2 and TNF-α re-
leased from cells treated with PD98059 or 
SP600125. In contrast to UA, both inhibi-
tors inhibit the PMA/PHA-induced IL-2 
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and TNF-α production without pretreatment 
(Figure 3c, d). However, inhibition of TNF-
α production by PD98059 is less effective 
compared with that of SP600125. The IL-2 
and TNF-α level after treatment with 
PMA/PHA were measured as 9,551.48  
935.90 pg mg-1 protein and 938.04  85.03 
pg mg-1 protein, respectively (dashed lines). 
 
 
 
 
 
 
Figure 3: Effect of UA and MAPK inhibitors on 
inhibition of PMA/PHA-induced IL-2 and TNF- 
production. Cells were treated with DMSO (con-
trol), UA, PD98059 or SP600125 for 0 to 12 
hours and then stimulated with PMA/PHA for a 
further 12 hours. The IL-2 (a), (c) and TNF- 
(b), (d) were determined using ELISA. Results 
are expressed as mean  SEM from three in-
dependent experiments. Statistical analyses 
were carried out with one-way ANOVA followed 
by Tukey’s multiple comparison test compared 
with positive controls (PMA/PHA) (* P < 0.05,  
** P < 0.01, *** P < 0.001).  
 
 
Effect of UA and PMA/PHA on MAPK 
activation and expression in Jurkat  
leukemic T-cells 
We have shown in our previous results 
that PMA/PHA and not UA induce cyto-
kine release from the Jurkat cells. As 
MAPK pathway proteins are involved in 
cytokine production, we therefore investi-
gated the expression and phosphorylation of 
ERK and JNK proteins in cells treated with 
PMA/PHA or UA. Western blot analyses 
were performed from three independent ex-
periments to determine the level of each 
protein, corresponding to the intensity of 
the protein bands. Western blot analysis of 
the proteins from cells treated with 
PMA/PHA (Figure 4a) represents the ex-
pression of phosphorylated ERK1/2 (p-
ERK1/2), ERK1/2 and β-actin. The highest 
relative level of p-ERK1/2 is seen at 24 
hours (Figure 4b) and relative level of 
ERK1/2 expression does not change com-
pared with control cells (Figure 4c). The 
relative ratio between p-ERK1/2 and 
a 
b
c
d
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ERK1/2 level reveals that PMA/PHA in-
duces maximal phosphorylation of ERK 
significantly at 24 hours (Figure 4d). Figure 
4e represents the expression of phosphory-
lated JNK (p-JNK), JNK, and β-actin from 
cells treated with PMA/PHA. The highest 
significant relative level of p-JNK occurs at 
1 hour but the p-JNK level is decreased 
significantly from 6 hours until 24 hours of 
treatment (Figure 4f). The relative level of 
JNK does not change compared with that of 
control cells (Figure 4g). Relative ratio be-
tween p-JNK and JNK level indicates that 
PMA/PHA significantly induces maximal 
phosphorylation of JNK at 1 hour. Howev-
er, it also significantly inhibits phosphory-
lation of JNK from 6 hours to 24 hours 
(Figure 4h). 
 
Figure 4: Effect of PMA/PHA on the activity of ERK1/2 and JNK in Jurkat leukemic T-cells; Western blot analysis 
(representative figure of three independent experiments). Cells were incubated with PMA/PHA for 1 to 24 hours, 
or only DMSO (C) for 24 hours. Protein expression of (a) p-ERK1/2 (42, 44 kDa), ERK1/2 (42, 44 kDa) and -
actin (45kDa) was detected by Western blot and normalized with -actin. (b), (c), (d) Relative p-ERK, ERK and p-
ERK/ERK protein level was calculated. Protein expression of (e) p-JNK (46, 54 kDa), JNK (46, 54 kDa) and -
actin (45kDa) was detected by Western blot and normalized with -actin. (f), (g), (h) Relative p-JNK, JNK and p-
JNK/JNK protein level was calculated. Statistical analysis was carried out with one-way ANOVA followed by Tuk-
ey’s multiple comparison test compared with positive controls (PMA/PHA) (* P < 0.05, ** P < 0.01) 
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Figure 5a shows expression of p-
ERK1/2, ERK1/2 and β-actin. Maximum 
relative level of p-ERK is found at 24 hours 
(Figure 5b) and there is no change in the 
expression level of ERK1/2 (Figure 5c) 
compared with that of the control. Relative 
ratio between p-ERK1/2 and ERK1/2 level 
indicates that UA, similar to PMA/PHA, 
significantly induces ERK phosphorylation 
at 24 hours (Figure 5d). Figure 5e repre-
sents expression of p-JNK, JNK and β-
actin. The relative level of p-JNK is signifi-
cantly reduced from 3 to 24 hours, except at 
12 hours (Figure 5f), whereas relative level 
of JNK is decreased from 3 hours with sig-
nificant reduction at 18 and 24 hours (Fig-
ure 5g). However, relative ratio between p-
JNK and JNK level shows no significant 
difference from that of the control, which 
indicates that the reduction of p-JNK is not 
caused by the inhibition effect but rather 
suppression of JNK expression by UA 
(Figure 5h).  
 
Inhibition of PMA/PHA-induced IL-2 and 
TNF-α production by ursolic acid via the 
JNK pathway 
We have shown that PD98059, 
SP600125 and UA inhibited PMA/PHA-
induced IL-2 and TNF-α production of 
Jurkat cells. However, UA inhibits IL-2 and 
TNF-α production in a concentration and 
time dependent manner, furthermore, with 
UA pretreatment is required. We suspected 
that inhibition of IL-2 and TNF-α produc-
tion might involve the MAPK pathways. 
Therefore, at the time points where we saw 
inhibition of IL-2 and TNF-α production by 
UA, we investigated the activation and ex-
pression of MAPK proteins inside the cells. 
Three independent Western blot analyses 
were performed to determine the level of 
each protein. Western blot analysis shows 
the highest intensity of p-ERK1/2 (Figure 
6a) and the maximum relative level of p-
ERK1/2 at 12 hours of UA treatment prior 
to the addition of PMA/PHA (Figure 6b). 
The relative level of ERK1/2 does not 
change compared with that of control (Fig-
ure 6c). The relative ratio between p-
ERK1/2 and ERK1/2 level shows that pre-
incubation of Jurkat cells with UA 20 µM 
for 12 hours prior to the addition of 
PMA/PHA, results in maximal p-ERK1/2 
level (Figure 6d). The induction of p-
ERK1/2 follows a trend similar to that of 
cells treated with either PMA/PHA or UA 
alone (Figure 4d, 5d). 
Western blot analysis shows that a 
longer UA treatment time prior to the addi-
tion of PMA/PHA, results in lower expres-
sion of p-JNK and JNK (Figure 6e). The 
relative level of p-JNK and JNK expression 
shows significant reduction from 4 hours 
for the p-JNK and 6 hours for the JNK re-
spectively (Figure 6f and 6g). The relative 
ratio between p-JNK and JNK level shows 
no significant difference between control 
and UA treatment prior to PMA/PHA stim-
ulation (Figure 6h). This indicates that the 
reduction of p-JNK is caused by suppres-
sion JNK protein such that only a low 
amount of JNK is available for phosphory-
lation. From our previous results, we have 
shown that PMA/PHA can induce phos-
phorylation of JNK in the first hour of 
treatment. However, this result shows that 
pretreatment of UA can decrease PMA/ 
PHA-induced p-JNK due to JNK suppres-
sion. 
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Figure 5: Effect of UA on the activity of ERK1/2 and JNK in Jurkat leukemic T-cell; Western blot anal-
ysis (representative figure of three independent experiments). Cells were incubated with 20 µM UA for 
1 to 24 hours, or only DMSO (C) for 24 hours. Protein expression of (a) p-ERK1/2 (42, 44 kDa), 
ERK1/2 (42, 44 kDa) and β-actin (45kDa) was detected by Western blot and normalized with β-actin. 
(b), (c), (d) Relative p-ERK, ERK and p-ERK/ERK protein levels were calculated. Protein expression 
of (e) p-JNK (46, 54 kDa), JNK (46, 54 kDa) and β-actin (45kDa) were detected by Western blot and 
normalized with β-actin. (f), (g), (h) Relative p-JNK, JNK and p-JNK/JNK protein levels were calculat-
ed. Statistical analysis was carried out with one-way ANOVA followed by Tukey’s multiple comparison 
test compared with positive controls (PMA/PHA) (* P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 
0.0001). 
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Figure 6: Inhibition of PMA/PHA induced-IL-2 and TNF- production by ursolic acid via the JNK pathway; West-
ern blot analysis (representative figure of three independent experiments). Cell were pre-incubated with UA for 0 
to 12 hours, PD98059 or SP600125 for 12 hours prior to addition of PMA/PHA for a further 12 hours, or only 
DMSO (C) for 24 hours. For positive control (P) cells were left without treatment for 12 hours prior to addition of 
PMA/PHA for a further 12 hours. Protein expression of (a) p-ERK1/2 (42, 44 kDa), ERK1/2 (42, 44 kDa) and -
actin (45kDa) was detected by Western blot and normalized with -actin. (b), (c), (d) Relative p-ERK, ERK and p-
ERK/ERK protein level was calculated. Protein expression of (e) p-JNK (46, 54 kDa), JNK (46, 54 kDa) and -
actin (45kDa) was detected by Western blot and normalized with -actin. (f), (g), (h) Relative p-JNK, JNK and p-
JNK/JNK protein level was calculated. Statistical analysis was carried out with one-way ANOVA followed by Tuk-
ey’s multiple comparison test compared with positive controls (PMA/PHA) (* P < 0.05, ** P < 0.01, *** P < 0.001, 
**** P < 0.0001). 
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DISCUSSION 
With anticancer properties via inhibition 
of cell proliferation, UA inhibits the growth 
of many cancerous cells such as human HT-
29 colon cancer cells, Burkitt lymphoma 
P3HR1 cells and chronic myelogenous leu-
kemia K562 cells with IC50 values ranging 
from 5-40 µM, depending on cell type and 
length of treatment (Chiang et al., 2003; 
Shan et al., 2009). Our study shows that UA 
inhibits the growth of Jurkat cells with an 
IC50 of 32.5 µM, percentage cell viability 
inversely corresponds with UA concentra-
tion and treatment time, and cell viability is 
significantly decreased with concentrations 
higher than the IC50 for UA. We also 
demonstrate that UA does not stimulate, 
rather it suppresses PMA/PHA induced IL-
2 and TNF-α production in a concentration 
and time dependent manner. With a high 
concentration of UA, both IL-2 and TNF-α 
production are significantly inhibited at ear-
ly time points. However, even at high con-
centrations, UA shows little inhibition of 
cytokine production unless it was pre-
incubated with cells prior to PMA/PHA 
stimulation, suggesting that UA has a de-
layed effect on inhibition of IL-2 and TNF-
α production. IL-2 is known to promote cell 
proliferation, inhibit apoptosis and induce 
cytokine production in many cells; it is also 
necessary for the regulation of T-cell func-
tion. TNF-α is a pro-inflammatory cyto-
kine, which is important in the regulation of 
immune cells, induction of apoptosis and 
the induction of other cytokines (O'Shea et 
al., 2002; Nelson, 2004; Bradley, 2008). 
Taken together, Jurkat cell proliferation is 
inhibited by a reduction in cytokine produc-
tion. UA does not always inhibit cytokine 
production; according to a study showing 
that aggregated UA binding with CD36 in-
duced IL-1β secretion through the p38 
MAPK, ERK1/2 pathways and caspase-1 
activation in RAW264.7 mouse macro-
phage cells (Ikeda et al., 2007). 
Although many studies have shown that 
UA can inhibit cytokines (Ikeda et al., 
2008; Manu and Kuttan, 2008; Checker et 
al., 2012), and induce apoptosis through 
JNK pathway stimulation in Jurkat cells 
(Liu and Jiang, 2007; Dhanasekaran and 
Reddy, 2008; Gao et al., 2012), these stud-
ies have not clarified the involvement or 
relationship between inhibition of PMA/ 
PHA-induced cytokine production by UA 
and the MAPK signaling pathway in human 
leukemia T-cells. Firstly we demonstrated 
that IL-2 and TNF-α production are in-
volved both the ERK and JNK pathway us-
ing PD98059 and SP600125. We also found 
that both UA and PD98059 inhibit IL-2 and 
TNF-α production but UA does not inhibit 
phosphorylation of ERK as PD98059 does, 
instead it induces phosphorylation of ERK. 
The results suggest that inhibition of IL-2 
and TNF-α production by UA may not be 
related to the ERK pathway and the mecha-
nisms of cytokine inhibition by UA and 
ERK inhibitor are likely to be regulated dif-
ferently. Activation of the JNK pathway is 
required for the gene expression of many 
cytokines, especially IL-2 in T cells (Isakov 
and Altman, 2002). We found that JNK ex-
pression is significantly suppressed, sug-
gesting that the inhibition of cytokine pro-
duction by UA involves the JNK pathway 
but not the ERK pathway. From our results, 
PMA/PHA induces JNK phosphorylation in 
the early hours of treatment and cytokine 
production occurs later on. UA, with pre-
treatment prior to PMA/PHA stimulation, 
does not directly inhibit PMA/PHA-
induced JNK phosphorylation, but rather 
suppresses JNK expression. Only a low 
amount of JNK remains to be phosphory-
lated as a result of PMA/PHA treatment. 
Longer UA pretreatment, also significantly 
inhibits PMH/PHA-induced cytokine pro-
duction. Taken together, JNK suppression 
by UA, results in insufficient JNK to be 
phosphorylated by PMA/PHA such that 
production of cytokines is consequently in-
hibited. Inhibition of cytokine production 
through JNK pathway, especially IL-2 and 
TNF-α in T cells leads to retardation of cell 
growth and activation. 
However, IL-2 expression may not be 
restricted to the JNK pathway, as a previous 
study has demonstrated that expression of a 
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dominant negative ERK mutant in Jurkat 
cells results in the suppression of IL-2 pro-
duction. (Li et al., 1999). Investigations into 
other signaling pathway proteins and their 
mechanisms such as PKC, MKK4, MKK7, 
c-Jun or transcription factors such as AP-1 
should be carried out, as they may be in-
volved in cytokine inhibition by UA. PMA-
induced PKC activation stimulates AP-1 
transcription factor via the JNK pathway, 
resulting in an increase of IL-2 gene ex-
pression (Isakov and Altman, 2002; Gaffen 
and Liu, 2004; Karin and Gallagher, 2005). 
However, induction of IL-2 gene expres-
sion by activation of AP-1 through the ERK 
pathway does not involve PKC (Gaffen and 
Liu, 2004). Although further evaluation of 
the mechanisms involved is required, UA’s 
ability to induce apoptosis and inhibit cell 
proliferation makes it a great candidate for 
use as an anticancer/leukemia drug. How-
ever, it is also necessary to investigate the 
toxicity of UA on normal blood cells before 
further clinical research into the therapeutic 
potential of UA. 
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